19 December 2025 - Boehringer Ingelheim’s Jascayd (nerandomilast) tablets has been approved by the US FDA for the treatment of progressive pulmonary fibrosis in adults.

This represents a new treatment option in the US for this debilitating lung condition, with Jascayd being the first and only preferential phosphodiesterase 4B inhibitor with immunomodulatory and anti-fibrotic effects approved in this indication.

Read Boehringer Ingelheim press release